Empowered by extensive experience and state-of-the-art equipment, Creative Biolabs has been a world-leading custom manufacturer in the area of antibody discovery and immunotherapy. Now, we are proud to introduce our full package service of investigational new drug (IND) development for chimeric antigen receptor (CAR) T cell therapy.
Cell-based immunotherapies using CAR-T cells have demonstrated high response rates in patients with B cell malignancies. Currently, this therapy is being investigated in both hematologic and solid tumor types. As more and more CAR-T cell therapies aim to move into clinical trials and become promising treatment options for more patients, IND development is required and becomes a topic for extensive discussion. However, it is challenging from the experiment design, project management, to the file preparation of each module based on regulations from Food and Drug Administration (FDA) for most scientists who are not expert at them. Therefore, Creative Biolabs, who has been in the field for years, offers the IND development service for CAR-T cell therapy to solve your troubles during the whole IND process.
Figure 1. The procedure of CAR-T cell therapy.
One-Stop IND Development Service
As an experienced company, Creative Biolabs deeply understands FDA’s current requirements on this item. There are two fundamental purposes for FDA to review an IND. The first one is to ensure the safety and rights of subjects in all phases of an investigation. The second is to help ensure that the quality of the scientific evaluation of the drug is sufficient to permit an evaluation of the drug’s safety and effectiveness in phases 2 and 3. A full IND development process includes the pre-IND process, the IND study protocol, preparing the initial IND submission, filing the IND, maintaining the IND. The pre-IND process is served in determining if your study qualifies for exemption from an IND. A fully developed clinical protocol is the basis for the initial IND submission. Preparing the initial IND submission includes an IND application form (contains animal pharmacology and toxicology studies, manufacturing information), a cover letter, a ClinicalTrials.gov certification of compliance. Our one-stop IND development service can free up your valuable time, helping you complete the whole IND process from the pre-IND process to maintaining the IND.
Figure 2. Drug development phases from research stage up to marketing; NDA = New Drug Application, SNDAs = Supplemental New Drug Application.
Highlight Features of Our Service
Since we have years of experience in the immunotherapy area, we have performed the whole series of CAR-T cell discovery for our worldwide customers. Therefore, we are confident in meeting the IND requirements with a high success rate.
Our Ph.D-level scientific team is rich of experience and familiar with FDA’s regulations certainly including IND development.
Our one-stop service can make you free from all the lab experiments and tedious regulations.
We are proficient in every process of IND Development. Choosing Creative Biolabs can certainly increase the possibility of passing. if you are interested in our service, please feel free to contact us for more information.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE